JP2025517908A - 抗ｃｄｈ６抗体－薬物コンジュゲートの投薬量レジメン - Google Patents

抗ｃｄｈ６抗体－薬物コンジュゲートの投薬量レジメン Download PDF

Info

Publication number
JP2025517908A
JP2025517908A JP2024567538A JP2024567538A JP2025517908A JP 2025517908 A JP2025517908 A JP 2025517908A JP 2024567538 A JP2024567538 A JP 2024567538A JP 2024567538 A JP2024567538 A JP 2024567538A JP 2025517908 A JP2025517908 A JP 2025517908A
Authority
JP
Japan
Prior art keywords
antibody
cancer
drug conjugate
drug
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024567538A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025517908A5 (enExample
Inventor
マクラウド，ロバート
佑典 明畠
智路 石坂
由美 西矢
智枝美 齊藤
宏和 鈴木
翔太郎 長瀬
ヴー クラヴェイロ，トゥイ
スブラマニアン，クランダヤン
リン，ジエ
大悟 浅野
ウルタード，フェリペ ケラーマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of JP2025517908A publication Critical patent/JP2025517908A/ja
Publication of JP2025517908A5 publication Critical patent/JP2025517908A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2024567538A 2022-05-24 2023-05-23 抗ｃｄｈ６抗体－薬物コンジュゲートの投薬量レジメン Pending JP2025517908A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263345286P 2022-05-24 2022-05-24
US63/345,286 2022-05-24
PCT/IB2023/055316 WO2023228095A1 (en) 2022-05-24 2023-05-23 Dosage regimen of an anti-cdh6 antibody-drug conjugate

Publications (2)

Publication Number Publication Date
JP2025517908A true JP2025517908A (ja) 2025-06-12
JP2025517908A5 JP2025517908A5 (enExample) 2025-11-27

Family

ID=86692863

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024567538A Pending JP2025517908A (ja) 2022-05-24 2023-05-23 抗ｃｄｈ６抗体－薬物コンジュゲートの投薬量レジメン

Country Status (11)

Country Link
US (1) US20250082771A1 (enExample)
EP (1) EP4531927A1 (enExample)
JP (1) JP2025517908A (enExample)
KR (1) KR20250012631A (enExample)
CN (1) CN119255825A (enExample)
AU (1) AU2023274540A1 (enExample)
CA (1) CA3256230A1 (enExample)
IL (1) IL317192A (enExample)
MX (1) MX2024014484A (enExample)
TW (1) TW202404646A (enExample)
WO (1) WO2023228095A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor
WO2026120507A1 (en) 2024-12-04 2026-06-11 Daiichi Sankyo Company, Limited An antibody-drug conjugate for use in the treatment of drug-resistant cancer

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018212136A1 (ja) * 2017-05-15 2018-11-22 第一三共株式会社 抗ｃｄｈ６抗体及び抗ｃｄｈ６抗体－薬物コンジュゲート
WO2020022363A1 (ja) * 2018-07-25 2020-01-30 第一三共株式会社 抗体－薬物コンジュゲートの効果的な製造方法
WO2020022475A1 (ja) * 2018-07-27 2020-01-30 第一三共株式会社 抗体－薬物コンジュゲートの薬物部位を認識する蛋白質
WO2020027100A1 (ja) * 2018-07-31 2020-02-06 第一三共株式会社 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療
WO2020031936A1 (ja) * 2018-08-06 2020-02-13 第一三共株式会社 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ
WO2020122034A1 (ja) * 2018-12-11 2020-06-18 第一三共株式会社 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ
WO2020130125A1 (ja) * 2018-12-21 2020-06-25 第一三共株式会社 抗体－薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
US20220089737A1 (en) * 2020-09-11 2022-03-24 Janssen Biotech, Inc. Multi-specific immune targeting molecules and uses thereof
WO2022102634A1 (ja) * 2020-11-11 2022-05-19 第一三共株式会社 抗体－薬物コンジュゲートと抗ＳＩＲＰα抗体の組み合わせ

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
CA2177367A1 (en) 1993-12-03 1995-06-08 Andrew David Griffiths Recombinant binding proteins and peptides
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
ES2706547T3 (es) 1998-12-23 2019-03-29 Pfizer Anticuerpos monoclonales humanos para CTLA-4
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
PT1244647E (pt) 1999-11-05 2006-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
HRP20020751B1 (hr) 2000-02-15 2011-01-31 Sugen Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
MXPA03005696A (es) 2000-12-21 2003-10-06 Glaxo Group Ltd Pirimidinaminas como moduladores de angiogenesis.
EP1382604B1 (en) 2001-04-27 2005-12-28 Kirin Beer Kabushiki Kaisha Quinoline derivative having azolyl group and quinazoline derivative
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
WO2014022975A1 (zh) 2012-08-07 2014-02-13 上海创诺医药集团有限公司 N-(4-(3-氨基-1h-吲唑-4-基)苯基)-n'-(2-氟-5-甲基苯基)脲及其中间体的制备方法
US10195288B2 (en) 2012-10-11 2019-02-05 Daiichi Sankyo Company, Limited Antibody-drug conjugate
SG10201902571VA (en) 2013-12-25 2019-04-29 Daiichi Sankyo Co Ltd Anti-trop2 antibody-drug conjugate
MX2017001946A (es) 2014-08-12 2017-06-19 Novartis Ag Conjugados de farmacos con anticuerpos anti-cdh6.
US20240390512A1 (en) 2021-09-15 2024-11-28 Daiichi Sankyo Company, Limited Methods of treating chemotherapy-resistant cancer with an antibody-drug conjugate

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018212136A1 (ja) * 2017-05-15 2018-11-22 第一三共株式会社 抗ｃｄｈ６抗体及び抗ｃｄｈ６抗体－薬物コンジュゲート
WO2020022363A1 (ja) * 2018-07-25 2020-01-30 第一三共株式会社 抗体－薬物コンジュゲートの効果的な製造方法
WO2020022475A1 (ja) * 2018-07-27 2020-01-30 第一三共株式会社 抗体－薬物コンジュゲートの薬物部位を認識する蛋白質
WO2020027100A1 (ja) * 2018-07-31 2020-02-06 第一三共株式会社 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療
WO2020031936A1 (ja) * 2018-08-06 2020-02-13 第一三共株式会社 抗体－薬物コンジュゲートとチューブリン阻害剤の組み合わせ
WO2020122034A1 (ja) * 2018-12-11 2020-06-18 第一三共株式会社 抗体－薬物コンジュゲートとｐａｒｐ阻害剤の組み合わせ
WO2020130125A1 (ja) * 2018-12-21 2020-06-25 第一三共株式会社 抗体－薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
US20220089737A1 (en) * 2020-09-11 2022-03-24 Janssen Biotech, Inc. Multi-specific immune targeting molecules and uses thereof
WO2022102634A1 (ja) * 2020-11-11 2022-05-19 第一三共株式会社 抗体－薬物コンジュゲートと抗ＳＩＲＰα抗体の組み合わせ

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CARL U. BIALUCHA ET AL.: "Discovery and Optimization of HKT288, a Cadherin-6Targeting ADC for the Treatment of Ovarian and Ren", CANCER DISCOVERY, vol. 7, no. 9, JPN6026007151, 31 August 2017 (2017-08-31), pages 1030 - 1045, ISSN: 0005802920 *
JAIME PRAT: "Staging classification for cancer of the ovary, fallopian tube, and peritoneum", INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, vol. 124, no. 1, JPN6026007153, 22 October 2013 (2013-10-22), pages 1 - 5, ISSN: 0005802922 *
MARTIN KBEL ET AL.: "Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies", PLOS MEDICINE, vol. 5, no. 12, JPN6026007152, 2 December 2008 (2008-12-02), pages 232, ISSN: 0005802921 *

Also Published As

Publication number Publication date
AU2023274540A1 (en) 2024-12-12
KR20250012631A (ko) 2025-01-24
IL317192A (en) 2025-01-01
EP4531927A1 (en) 2025-04-09
CN119255825A (zh) 2025-01-03
CA3256230A1 (en) 2023-11-30
US20250082771A1 (en) 2025-03-13
MX2024014484A (es) 2025-04-02
TW202404646A (zh) 2024-02-01
WO2023228095A1 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
JP7705809B2 (ja) 抗体薬物複合体の用量
US11077202B2 (en) Anti-CDH6 antibody and anti-CDH6 antibody-drug conjugate
TWI827534B (zh) 含抗ｈｅｒ２抗體-藥物結合物之治療劑之用途
JP2022037170A (ja) 癌治療用のａｘｌ特異的抗体－薬物コンジュゲート
CN110382535A (zh) 抗-gpr20抗体以及抗-gpr20抗体-药物缀合物
TWI862982B (zh) 抗體–藥物結合物之用途
US20250082771A1 (en) Dosage regimen of an anti-cdh6 antibody-drug conjugate
CN113195541A (zh) 针对pmel17的抗体及其缀合物
TW202330041A (zh) 抗cd37抗體-藥物結合物
AU2021378152A1 (en) COMBINATION OF AN ANTIBODY-DRUG CONJUGATE WITH ANTI-SIRPα ANTIBODY
TW202444760A (zh) 抗ｃｄ２５抗體及抗ｃｄ２５抗體－藥物複合體
HK40027154B (en) Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20250127

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20241113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251118

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20251118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260624